Literature DB >> 27472882

Active Cigarette Smoking in Cognitively-Normal Elders and Probable Alzheimer's Disease is Associated with Elevated Cerebrospinal Fluid Oxidative Stress Biomarkers.

Timothy C Durazzo1,2, Magdalena Korecka3, John Q Trojanowski3, Michael W Weiner4,5, Ruth O' Hara1,2, John W Ashford1,2, Leslie M Shaw3.   

Abstract

Neurodegenerative diseases and chronic cigarette smoking are associated with increased cerebral oxidative stress (OxS). Elevated F2-isoprostane levels in biological fluid is a recognized marker of OxS. This study assessed the association of active cigarette smoking with F2-isoprostane in concentrations in cognitively-normal elders (CN), and those with mild cognitive impairment (MCI) and probable Alzheimer's disease (AD). Smoking and non-smoking CN (n = 83), MCI (n = 164), and probable AD (n = 101) were compared on cerebrospinal fluid (CSF) iPF2α-III and 8,12, iso-iPF2α-VI F2-isoprostane concentrations. Associations between F2-isoprostane levels and hippocampal volumes were also evaluated. In CN and AD, smokers had higher iPF2α-III concentration; overall, smoking AD showed the highest iPF2α-III concentration across groups. Smoking and non-smoking MCI did not differ on iPF2α-III concentration. No group differences were apparent on 8,12, iso-iPF2α-VI concentration, but across AD, higher 8,12, iso-iPF2α-VI level was related to smaller left and total hippocampal volumes. Results indicate that active cigarette smoking in CN and probable AD is associated with increased central nervous system OxS. Further investigation of factors mediating/moderating the absence of smoking effects on CSF F2-isoprostane levels in MCI is warranted. In AD, increasing magnitude of OxS appeared to be related to smaller hippocampal volume. This study contributes additional novel information to the mounting body of evidence that cigarette smoking is associated with adverse effects on the human central nervous system across the lifespan.

Entities:  

Keywords:  Alzheimer’s disease; F2-isoprostanes; cigarette smoking; hippocampus; mild cognitive impairment

Mesh:

Substances:

Year:  2016        PMID: 27472882      PMCID: PMC5127393          DOI: 10.3233/JAD-160413

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  48 in total

1.  Biomarkers of oxidative damage in cigarette smokers: which biomarkers might reflect acute versus chronic oxidative stress?

Authors:  Raymond C S Seet; Chung-Yung J Lee; Wai Mun Loke; Shan Hong Huang; Huiwen Huang; Woan Foon Looi; Eng Soh Chew; Amy M L Quek; Erle C H Lim; Barry Halliwell
Journal:  Free Radic Biol Med       Date:  2011-03-17       Impact factor: 7.376

Review 2.  F2-isoprostanes as markers of oxidative stress in vivo: an overview.

Authors:  Ginger L Milne; Erik S Musiek; Jason D Morrow
Journal:  Biomarkers       Date:  2005-11       Impact factor: 2.658

3.  Cortical surface-based analysis. II: Inflation, flattening, and a surface-based coordinate system.

Authors:  B Fischl; M I Sereno; A M Dale
Journal:  Neuroimage       Date:  1999-02       Impact factor: 6.556

4.  Impact of apolipoprotein E4-cerebrospinal fluid β-amyloid interaction on hippocampal volume loss over 1 year in mild cognitive impairment.

Authors:  Gloria C Chiang; Philip S Insel; Duygu Tosun; Norbert Schuff; Diana Truran-Sacrey; Sky T Raptentsetsang; Paul M Thompson; Eric M Reiman; Clifford R Jack; Nick C Fox; William J Jagust; Danielle J Harvey; Laurel A Beckett; Anthony Gamst; Paul S Aisen; Ron C Petersen; Michael W Weiner
Journal:  Alzheimers Dement       Date:  2011-09       Impact factor: 21.566

5.  Nomenclature of isoprostanes: a proposal.

Authors:  J Rokach; S P Khanapure; S W Hwang; M Adiyaman; J A Lawson; G A FitzGerald
Journal:  Prostaglandins       Date:  1997-12

6.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.

Authors:  Leslie M Shaw; Hugo Vanderstichele; Malgorzata Knapik-Czajka; Christopher M Clark; Paul S Aisen; Ronald C Petersen; Kaj Blennow; Holly Soares; Adam Simon; Piotr Lewczuk; Robert Dean; Eric Siemers; William Potter; Virginia M-Y Lee; John Q Trojanowski
Journal:  Ann Neurol       Date:  2009-04       Impact factor: 10.422

7.  Dissociable effects of Alzheimer disease and white matter hyperintensities on brain metabolism.

Authors:  Thaddeus J Haight; Susan M Landau; Owen Carmichael; Christopher Schwarz; Charles DeCarli; William J Jagust
Journal:  JAMA Neurol       Date:  2013-08       Impact factor: 18.302

8.  Low intensity, long term exposure to tobacco smoke inhibits hippocampal neurogenesis in adult mice.

Authors:  Dávid Csabai; Kata Csekő; Lilla Szaiff; Zsófia Varga; Attila Miseta; Zsuzsanna Helyes; Boldizsár Czéh
Journal:  Behav Brain Res       Date:  2016-01-12       Impact factor: 3.332

9.  Three midlife strategies to prevent cognitive impairment due to Alzheimer's disease.

Authors:  V W Henderson
Journal:  Climacteric       Date:  2014-08-17       Impact factor: 3.005

Review 10.  Prostanoid and isoprostanoid pathways in atherogenesis.

Authors:  Domenico Praticò
Journal:  Atherosclerosis       Date:  2008-04-29       Impact factor: 5.162

View more
  11 in total

Review 1.  Supraphysiologic-dose anabolic-androgenic steroid use: A risk factor for dementia?

Authors:  Marc J Kaufman; Gen Kanayama; James I Hudson; Harrison G Pope
Journal:  Neurosci Biobehav Rev       Date:  2019-02-25       Impact factor: 8.989

2.  Short-term E-cigarette toxicity effects on brain cognitive memory functions and inflammatory responses in mice.

Authors:  E S Prasedya; Y Ambana; N W R Martyasari; Ye'muh Aprizal
Journal:  Toxicol Res       Date:  2020-02-04

Review 3.  Cardiovascular injury induced by tobacco products: assessment of risk factors and biomarkers of harm. A Tobacco Centers of Regulatory Science compilation.

Authors:  Daniel J Conklin; Suzaynn Schick; Michael J Blaha; Alex Carll; Andrew DeFilippis; Peter Ganz; Michael E Hall; Naomi Hamburg; Tim O'Toole; Lindsay Reynolds; Sanjay Srivastava; Aruni Bhatnagar
Journal:  Am J Physiol Heart Circ Physiol       Date:  2019-02-01       Impact factor: 4.733

Review 4.  Neurotoxicity of e-cigarettes.

Authors:  Joanna A Ruszkiewicz; Ziyan Zhang; Filipe Marques Gonçalves; Yousef Tizabi; Judith T Zelikoff; Michael Aschner
Journal:  Food Chem Toxicol       Date:  2020-03-05       Impact factor: 6.023

Review 5.  Recent advances in pre-clinical diagnosis of Alzheimer's disease.

Authors:  John Zhou; Marc Benoit; Md Golam Sharoar
Journal:  Metab Brain Dis       Date:  2021-04-26       Impact factor: 3.655

6.  The cut-off values of anthropometric variables for predicting mild cognitive impairment in Malaysian older adults: a large population based cross-sectional study.

Authors:  Huiloo Won; Manaf Zahara Abdul; Arimi Fitri Mat Ludin; Mohd Azahadi Omar; Rosdinom Razali; Suzana Shahar
Journal:  Clin Interv Aging       Date:  2017-02-07       Impact factor: 4.458

Review 7.  The Prevalence of Alzheimer's Disease in China: A Systematic Review and Meta-analysis.

Authors:  Kanglan Li; Shouchao Wei; Zhou Liu; Li Hu; Jiajing Lin; Shiting Tan; Yingren Mai; Wanjuan Peng; Hui Mai; Qi Hou; Guifeng Tu
Journal:  Iran J Public Health       Date:  2018-11       Impact factor: 1.429

8.  A history of cigarette smoking is associated with faster functional decline and reduction of entorhinal cortex volume in mild cognitive impairment.

Authors:  Mayun Chen; Chaoming Hu; Haoru Dong; Hanhan Yan; Peiliang Wu
Journal:  Aging (Albany NY)       Date:  2021-02-12       Impact factor: 5.682

Review 9.  Hypertension and Age-Related Cognitive Impairment: Common Risk Factors and a Role for Precision Aging.

Authors:  Meredith Hay; Carol Barnes; Matt Huentelman; Roberta Brinton; Lee Ryan
Journal:  Curr Hypertens Rep       Date:  2020-09-03       Impact factor: 5.369

10.  Factors Predicting the Onset of Amnestic Mild Cognitive Impairment or Alzheimer's Dementia in Persons With Subjective Cognitive Decline.

Authors:  Sangwoo Ahn; Michelle A Mathiason; Dereck Salisbury; Fang Yu
Journal:  J Gerontol Nurs       Date:  2020-08-01       Impact factor: 1.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.